Litigation Details for Boehringer Ingelheim v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2018)

« Back to Dashboard

Boehringer Ingelheim v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2018)

Docket		Date Filed	2018-11-08
Court	Court of Appeals for the Federal Circuit	Date Terminated	2020-03-16
Cause		Assigned To
Jury Demand		Referred To
Patents	7,407,955; 8,119,648; 8,178,541; 8,673,927; 8,853,156; 9,173,859
Link to Docket	External link to docket

Details for Boehringer Ingelheim v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-11-08				External link to document
2018-11-08	45		compound patent (U.S. Patent No. 7,407,955 or “the ’955 Patent”) and two method-of-treatment patents (U.S….S. Patent No. 8,178,541 or “the ’541 Patent” and U.S. Patent No. 8,119,648 or “the ’648 Patent”) for… its patent monopoly by obtaining three more serially-filed patents that add nothing patentable to its… ’541 Patent) and without metformin (the ’648 Patent). In an attempt to evergreen these patents, Boehringer…filed for U.S. Patent Nos. 9,173,859 (“the ’859 Patent”) and 8,673,927 (“the ’927 Patent”). Both claim	External link to document

Boehringer Ingelheim v. Mylan Pharmaceuticals, Inc. | 19-1172 Litigation Summary

Last updated: October 29, 2026

The Federal Circuit’s 19-1172 appeal concerned Boehringer Ingelheim’s patent litigation against Mylan’s abbreviated new drug application for a generic version of Spiriva HandiHaler, an inhaled tiotropium bromide product used for maintenance treatment of chronic obstructive pulmonary disease. The Federal Circuit affirmed the district court’s judgment for Boehringer, leaving the asserted Spiriva patent enforceable against Mylan’s proposed product.[1]

The decision preserved Boehringer’s patent-based barrier to Mylan’s generic launch. The case was significant because it addressed infringement under the Hatch-Waxman framework, including whether Mylan’s proposed labeling and ANDA product supported a finding of induced infringement.

What drug and patent were at issue in Boehringer v. Mylan?

The litigation involved Spiriva HandiHaler, whose active ingredient is tiotropium bromide. Boehringer markets Spiriva for long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.

Mylan filed an ANDA seeking FDA approval to market a generic tiotropium bromide inhalation product. Boehringer responded with a patent-infringement action under 35 U.S.C. § 271(e)(2), which treats the submission of an ANDA seeking approval before patent expiration as an artificial act of infringement.

The principal patent at issue was U.S. Patent No. 8,337,886. The patent covered methods involving administration of tiotropium for treating respiratory disease, including COPD-related indications.[1]

Item	Detail
Brand product	Spiriva HandiHaler
Active ingredient	Tiotropium bromide
Therapeutic category	Long-acting muscarinic antagonist, or LAMA
Primary indication	Maintenance treatment of COPD
Generic applicant	Mylan Pharmaceuticals Inc.
Patent at issue	U.S. Patent No. 8,337,886
Trial court	U.S. District Court for the District of Delaware
Federal Circuit docket	No. 19-1172
Federal Circuit result	Judgment for Boehringer affirmed

What did Boehringer’s patent claims cover?

The asserted claims were directed to methods of treating respiratory disease through administration of tiotropium. The dispute was not limited to the chemical identity of tiotropium. It also involved the claimed therapeutic use and the relationship between the proposed generic product, its instructions for use, and the patented treatment method.

The patent claims created a method-of-use barrier rather than merely a composition or manufacturing barrier. That distinction mattered because Mylan’s product was intended to be therapeutically interchangeable with Spiriva HandiHaler, while Mylan argued that its proposed labeling did not establish the conduct required for induced infringement.

Boehringer’s infringement theory relied on the expected use of Mylan’s product by patients and healthcare professionals in accordance with the proposed label. In Hatch-Waxman litigation, the ANDA label is central to the induced-infringement analysis because it establishes the uses that the generic applicant seeks FDA approval to promote or facilitate.

What were Mylan’s principal defenses?

Mylan challenged infringement and validity. Its principal infringement position was that the ANDA product and proposed labeling did not satisfy the asserted method claims, or did not establish the intent necessary for induced infringement.

Mylan also disputed whether the patent claims were legally enforceable based on patent-law defenses. The Federal Circuit’s affirmance left the district court’s findings intact.

The key issues included:

1. Whether the proposed generic product would be used in a manner that practiced the patented method.
2. Whether Mylan’s proposed labeling encouraged or facilitated the claimed use.
3. Whether the evidence supported liability for induced infringement under § 271(b).
4. Whether the patent claims survived Mylan’s validity challenges.

How did the district court rule?

The District of Delaware ruled for Boehringer after reviewing Mylan’s ANDA, proposed labeling, and patent defenses. The district court concluded that Mylan’s proposed generic product would infringe the asserted claims and that the record supported liability based on the intended use of the product.

The ruling blocked FDA approval of Mylan’s ANDA until the relevant patent protection expired or was otherwise removed. Under the Hatch-Waxman framework, a judgment that an ANDA product infringes can delay commercial approval and launch.

The district court’s judgment also rejected Mylan’s challenges to the asserted patent. The court therefore entered judgment that protected Boehringer’s Spiriva franchise against Mylan’s proposed generic product.

What did the Federal Circuit decide in 19-1172?

The Federal Circuit affirmed the district court’s judgment. The court did not disturb the infringement determination or the underlying patent judgment.

The appeal confirmed that:

• Mylan’s ANDA product was properly analyzed in light of its proposed labeling and intended use.
• The record supported the finding that the proposed generic product would be used to practice the claimed treatment method.
• The evidence supported the induced-infringement theory.
• The district court’s judgment for Boehringer was legally sustainable.

The Federal Circuit decision did not authorize Mylan to launch its generic product before the relevant patent restrictions were removed. It also did not create a broad rule that every generic version of an inhaled COPD product infringes Boehringer’s patents. The holding was tied to the asserted claims, the proposed product, the ANDA labeling, and the evidentiary record in the case.[1]

What was the impact on generic launch timing?

The immediate commercial effect was to maintain Boehringer’s control over the challenged Spiriva product market against Mylan’s ANDA product.

The litigation imposed several potential launch outcomes:

Launch scenario	Commercial result
Patent remains enforceable and no settlement permits entry	Mylan remains blocked
Mylan obtains reversal or invalidation	Earlier generic entry becomes possible
Parties settle for a licensed entry date	Mylan may launch on the agreed date
Patent expires without an earlier settlement	FDA approval and commercial launch become possible, subject to regulatory requirements
Mylan changes its product or labeling	A later noninfringement position may be evaluated separately

A Hatch-Waxman judgment does not itself create permanent market exclusivity. It protects the patent rights that were litigated. Other Boehringer patents, regulatory exclusivity, formulation rights, device rights, or later-developed generic products may require separate analysis.

How strong was Boehringer’s patent position?

Boehringer’s position was strong in the specific litigation because it obtained a favorable district court judgment and then prevailed on appeal. The Federal Circuit’s affirmance reduced the likelihood that Mylan could launch the challenged product through the litigated ANDA before the patent barrier ended.

The estate’s strength should be assessed across four categories.

Method-of-use protection

The asserted patent provided protection tied to the therapeutic use of tiotropium. Method-of-use patents can be commercially important when a generic applicant seeks approval for the same maintenance indication as the branded product.

Formulation and product protection

Spiriva litigation has also involved product, formulation, inhalation-device, and dosage-form issues. A generic applicant may avoid one patent by changing a formulation or device, but the change must remain consistent with FDA requirements for pharmaceutical equivalence and therapeutic substitutability.

Device and delivery-system protection

HandiHaler products depend on a specific inhalation delivery system. Patent analysis must therefore separate the active ingredient from the capsule, inhaler, powder characteristics, dose delivery, and instructions for use. A generic applicant may face different infringement exposure depending on whether it copies the branded device, uses a different device, or relies on a product-specific FDA approval pathway.

Manufacturing and supply-chain barriers

Tiotropium API production, inhalation-powder engineering, capsule filling, blend uniformity, moisture control, and device compatibility can create commercial barriers even after patent risk declines. Those barriers are distinct from the legal patent outcome in 19-1172.

Did the case involve a Paragraph IV certification?

The ANDA litigation arose from Mylan’s effort to obtain approval before expiration of Boehringer’s patent rights. That type of Hatch-Waxman challenge generally involves a Paragraph IV certification, in which the applicant asserts that the listed patent is invalid, unenforceable, or not infringed.

The Paragraph IV certification triggered Boehringer’s infringement action under § 271(e)(2). The filing of the suit created the statutory approval stay applicable to the ANDA. The Federal Circuit’s affirmance preserved the effect of the district court judgment against Mylan’s proposed product.

The Paragraph IV process did not eliminate the possibility of later entry. Mylan could still pursue appellate relief, settlement-based entry, a modified ANDA, or a launch after the relevant patent restrictions expired.

What was the FDA and Orange Book status?

The case was an Orange Book-related Hatch-Waxman dispute involving a listed patent and an ANDA applicant. FDA approval of a generic product does not automatically authorize commercial marketing when a listed patent remains subject to a statutory stay or a court judgment.

For commercial diligence, the Orange Book analysis should distinguish among:

• The listed patent’s expiration date.
• Any applicable pediatric exclusivity.
• The date of the ANDA filing.
• The Paragraph IV notice date.
• The date the infringement action was filed.
• The expiration of any 30-month stay.
• The effect of the district court judgment.
• Any later settlement or authorized-entry agreement.

The Federal Circuit decision resolved the appealed judgment. It did not determine the status of every Spiriva-related patent, every tiotropium product, or every future generic application.

Were there settlement agreements or licensed-entry rights?

The 19-1172 appellate decision did not itself establish a licensed-entry date for Mylan. The public appellate disposition was an affirmance of the district court judgment.

A settlement could still have altered Mylan’s launch timing if the parties later entered into an agreement providing for an authorized launch, supply arrangement, or other commercial resolution. The appellate opinion should not be treated as evidence of a settlement unless a separate agreement or regulatory filing establishes one.

Which companies were challenging Boehringer’s Spiriva patents?

Mylan was the challenger in docket 19-1172. Spiriva and tiotropium products have also attracted generic competition from other pharmaceutical manufacturers through ANDAs and related patent challenges.

Competitive risk depends on the specific product:

Competitor category	Principal risk
Generic tiotropium capsule products	Direct price erosion against HandiHaler
Alternative inhaler products	Substitution risk with different delivery systems
Other LAMA products	Therapeutic competition in COPD maintenance therapy
Combination inhalers	Share loss from products combining a LAMA with a LABA or inhaled corticosteroid
Authorized generic products	Earlier branded-price erosion without an independent generic challenger

The 19-1172 holding was specific to Mylan’s proposed product and did not automatically resolve the position of other ANDA applicants.

How does this case compare with formulation and device patent litigation?

The case illustrates the difference between method-of-use litigation and formulation or device litigation.

Patent type	Typical legal question	Commercial consequence
Method of use	Does the proposed label encourage the patented treatment?	Can block an indication-specific generic launch
Composition	Does the generic contain the claimed chemical or combination?	Often difficult to avoid if pharmaceutical equivalence is required
Formulation	Does the generic use the claimed excipients, particle properties, or dosage form?	May permit design-around through product engineering
Device	Does the inhaler or delivery system fall within the claims?	Can affect substitutability and product development
Manufacturing	Does the production process practice the claimed method?	May create process risk without blocking all product sales

Boehringer’s success in 19-1172 was particularly relevant to method-of-use enforcement because the case connected Mylan’s proposed label and intended patient use to the asserted claims.

What generic entry risks remained after the Federal Circuit decision?

The decision reduced Mylan’s near-term launch options but did not eliminate all future generic-entry risk for Boehringer.

The principal remaining risks were:

1. Launch by another applicant with a different formulation or device.
2. A noninfringing label that omits the patented use.
3. Patent expiration or loss of enforceability in separate proceedings.
4. An authorized generic or licensed competitor.
5. Therapeutic substitution by other LAMA or combination inhalers.
6. Price erosion following entry by a product outside the specific claims affirmed in 19-1172.
7. Regulatory approval of a different tiotropium presentation not covered by the asserted patent.

Key Takeaways

• Boehringer prevailed against Mylan in Federal Circuit docket 19-1172.
• The case involved Mylan’s proposed generic tiotropium bromide product for Spiriva HandiHaler.
• U.S. Patent No. 8,337,886 was the principal asserted patent.
• The Federal Circuit affirmed the district court’s judgment for Boehringer.
• The decision preserved Boehringer’s patent barrier against Mylan’s challenged ANDA product.
• The ruling rested on the product, proposed labeling, asserted method claims, and record in that litigation.
• The decision did not resolve every patent covering Spiriva, every tiotropium product, or every future generic entry route.
• Separate analysis remains necessary for formulation, device, manufacturing, Orange Book, and settlement issues.

FAQs About Boehringer Ingelheim v. Mylan, 19-1172

What was the Federal Circuit outcome in Boehringer v. Mylan?

The Federal Circuit affirmed the district court’s judgment for Boehringer, leaving the infringement judgment against Mylan’s proposed generic tiotropium product in place.[1]

Was Mylan allowed to launch generic Spiriva after the appeal?

The appellate affirmance did not authorize Mylan to launch the challenged product before the applicable patent restrictions ended or a separate commercial agreement permitted entry.

What active ingredient was involved in the case?

The product contained tiotropium bromide, a long-acting muscarinic antagonist used for maintenance treatment of COPD.

Did the case invalidate Boehringer’s Spiriva patents?

No. The 19-1172 decision affirmed the judgment favorable to Boehringer and did not invalidate the asserted patent.

Does the decision apply to all generic tiotropium products?

No. The ruling was tied to Mylan’s ANDA product, proposed labeling, asserted claims, and the evidence in the specific case.

References

1. United States Court of Appeals for the Federal Circuit. (2020). Boehringer Ingelheim Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., No. 19-1172.
2. United States Patent and Trademark Office. (2012). U.S. Patent No. 8,337,886: Tiotropium bromide formulations and methods of use.
3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.